Puma Biotechnology
PBYI
128 hedge funds and large institutions have $1.07B invested in Puma Biotechnology in 2016 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 61 increasing their positions, 24 reducing their positions, and 42 closing their positions.
154% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 24
92% more call options, than puts
Call options by funds: $23.6M | Put options by funds: $12.3M
2.53% more ownership
Funds ownership: 92.34% → 94.87% (+2.5%)
14% less funds holding
Funds holding: 149 → 128 (-21)
45% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 42
47% less capital invested
Capital invested by funds: $2.01B → $1.07B (-$938M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$72M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$49.5M |
| 3 |
State Street
Boston,
Massachusetts
|
+$44.7M |
| 4 |
Schroder Investment Management Group
London,
United Kingdom
|
+$28.3M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
+$27.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$69M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$61.2M |
| 3 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
-$15.6M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$10.9M |
| 5 |
Asset Management One
Tokyo,
Japan
|
-$8.96M |
PBYI Hedge Fund Activity: Q4 2016 in Review
128 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Puma Biotechnology (PBYI) for Q4 2016, worth a combined $1.07B — down 47% from $2.01B a quarter earlier.
Sellers outnumbered buyers: 42 funds closed out of PBYI and 23 opened new positions — a net loss of 19 holders — while 24 trimmed existing stakes and 61 added.
The largest buyer was Wellington Management Group, adding an estimated $72M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $69M sold.
- 128 institutional investors held Puma Biotechnology (PBYI) as of Q4 2016, down from 149 in Q3 2016.
- Funds reported $1.07B of Puma Biotechnology stock for Q4 2016, down 47% quarter-over-quarter.
- 23 funds opened new Puma Biotechnology positions in Q4 2016 and 42 closed out, a net change of -19 holders.
- The largest Puma Biotechnology buyer in Q4 2016 was Wellington Management Group, an estimated $72M added.
- The largest Puma Biotechnology seller in Q4 2016 was Point72 Asset Management, an estimated $69M sold.
Based on aggregated 13F filings for Q4 2016.